Skip to main content
. Author manuscript; available in PMC: 2023 Apr 26.
Published in final edited form as: Sci Transl Med. 2022 Aug 31;14(660):eabo6135. doi: 10.1126/scitranslmed.abo6135

Fig. 3. Natural COL6A3-FLNV–specific TCRs confer limited antitumor immunity in vivo.

Fig. 3.

(A) CD8 T cells were activated with anti-CD3/CD28 beads, transduced with the indicated TCR or left UTD, and stained with COL6A3-specific tetramer after 6 days of culture. Results are representative of three independent experiments with different donors performed in triplicate. (B) T cells from (A) after 11 days of culture were incubated with indicated artificial APCs (aAPCs) for 4 hours, and intracellular cytokine staining was performed. The average number of relevant pHLA copies per cell (pHLA-CpC) was determined by MS-based quantitation. Results are representative of three independent experiments with different donors performed in triplicate. Bioluminescence imaging of N6.COL6A3 (C) and N6.COL6A1 (D) tumors on the indicated days. Experimental schematic for in vivo study and survival curves of each on-target tumor group and off-target tumor groups can be found in fig. S5.